Details of the Drug

General Information of Drug (ID: DMS2IUH)

Drug Name
Valganciclovir
Synonyms
Cymeval; RS 79070; RO1079070/194; Valcyte (TN); Valganciclovir (INN); Valganciclovir (Oral); Valganciclovir [INN:BAN]; L-Valine, ester with ganciclovir; [2-[(2-amino-6-oxo-3H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate; L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-3-hydroxypropyl ester; 5-Amino-3-[1-(hydroxymethyl)-2-(L-valyloxy)ethoxymethyl]-6,7-dihydro-3H-imidazo[4,5-d]pyrimidin-7-one
Indication
Disease Entry ICD 11 Status REF
Virus infection 1A24-1D9Z Approved [1]
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 354.36
Logarithm of the Partition Coefficient (xlogp) -1.5
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 60% []
Half-life
The concentration or amount of drug in body reduced by one-half in 4.08 hours [3]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 84.6576 micromolar/kg/day [4]
Vd
The volume of distribution (Vd) of drug is 0.703 +/- 0.134 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 70 mg/mL [2]
Chemical Identifiers
Formula
C14H22N6O5
IUPAC Name
[2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
Canonical SMILES
CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
InChI
InChI=1S/C14H22N6O5/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22)/t8?,9-/m0/s1
InChIKey
WPVFJKSGQUFQAP-GKAPJAKFSA-N
Cross-matching ID
PubChem CID
135413535
ChEBI ID
CHEBI:63635
CAS Number
175865-60-8
DrugBank ID
DB01610
TTD ID
D06GWF
VARIDT ID
DR00404
ACDINA ID
D00716
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Herpes simplex virus DNA polymerase UL30 (HSV UL30) TTIU7X1 DPOL_HHV11 Inhibitor [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) DTW7AE3 AAAT_HUMAN Substrate [6]
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Valganciclovir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Valganciclovir caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [8]
Midostaurin DMI6E0R Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Midostaurin. Acute myeloid leukaemia [2A60] [8]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Valganciclovir and Inotersen. Amyloidosis [5D00] [9]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Valganciclovir and Roflumilast. Asthma [CA23] [9]
Eribulin DM1DX4Q Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Eribulin. Breast cancer [2C60-2C6Y] [8]
Talazoparib DM1KS78 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Talazoparib. Breast cancer [2C60-2C6Y] [8]
Ixabepilone DM2OZ3G Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Ixabepilone. Breast cancer [2C60-2C6Y] [8]
LY2835219 DM93VBZ Moderate Additive myelosuppressive effects by the combination of Valganciclovir and LY2835219. Breast cancer [2C60-2C6Y] [8]
Pralatrexate DMAO80I Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Pralatrexate. Breast cancer [2C60-2C6Y] [8]
Palbociclib DMD7L94 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Palbociclib. Breast cancer [2C60-2C6Y] [8]
Thiotepa DMIZKOP Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Thiotepa. Breast cancer [2C60-2C6Y] [8]
Cabazitaxel DMPAZHC Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Cabazitaxel. Breast cancer [2C60-2C6Y] [8]
Bosutinib DMTI8YE Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Bosutinib. Breast cancer [2C60-2C6Y] [8]
Aflibercept DMT3D5I Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Aflibercept. Colorectal cancer [2B91] [8]
Polatuzumab vedotin DMF6Y0L Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [8]
Lisocabtagene maraleucel DMP45ME Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Lisocabtagene maraleucel. Diffuse large B-cell lymphoma [2A81] [8]
Axicabtagene ciloleucel DMYHN59 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Axicabtagene ciloleucel. Diffuse large B-cell lymphoma [2A81] [8]
Bay 80-6946 DMLOS5R Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Bay 80-6946. Follicular lymphoma [2A80] [8]
Avapritinib DMK2GZX Moderate Increased risk of nephrotoxicity by the combination of Valganciclovir and Avapritinib. Gastrointestinal stromal tumour [2B5B] [8]
177Lu-DOTATATE DMT8GVU Moderate Additive myelosuppressive effects by the combination of Valganciclovir and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [8]
Brentuximab vedotin DMWLC57 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Brentuximab vedotin. Hodgkin lymphoma [2B30] [8]
Teriflunomide DMQ2FKJ Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Teriflunomide. Hyper-lipoproteinaemia [5C80] [8]
Lurbinectedin DMEFRTZ Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Lurbinectedin. Lung cancer [2C25] [8]
Osimertinib DMRJLAT Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Osimertinib. Lung cancer [2C25] [8]
Inotuzumab ozogamicin DMAC130 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [8]
Ofatumumab DM295PR Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Ofatumumab. Mature B-cell leukaemia [2A82] [8]
Obinutuzumab DM3BVAE Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Obinutuzumab. Mature B-cell leukaemia [2A82] [8]
Idelalisib DM602WT Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Idelalisib. Mature B-cell leukaemia [2A82] [8]
GDC-0199 DMH0QKA Moderate Additive myelosuppressive effects by the combination of Valganciclovir and GDC-0199. Mature B-cell leukaemia [2A82] [8]
IPI-145 DMWA24P Moderate Additive myelosuppressive effects by the combination of Valganciclovir and IPI-145. Mature B-cell leukaemia [2A82] [8]
Acalabrutinib DM7GCVW Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Acalabrutinib. Mature B-cell lymphoma [2A85] [8]
Blinatumomab DMGECIJ Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Blinatumomab. Mature B-cell lymphoma [2A85] [8]
Ibrutinib DMHZCPO Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Ibrutinib. Mature B-cell lymphoma [2A85] [8]
Tisagenlecleucel DMM9BJD Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Tisagenlecleucel. Mature B-cell lymphoma [2A85] [8]
Ponatinib DMYGJQO Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Ponatinib. Mature B-cell lymphoma [2A85] [8]
Carfilzomib DM48K0X Moderate Increased risk of nephrotoxicity by the combination of Valganciclovir and Carfilzomib. Multiple myeloma [2A83] [8]
Panobinostat DM58WKG Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Panobinostat. Multiple myeloma [2A83] [8]
Selinexor DMBD4K3 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Selinexor. Multiple myeloma [2A83] [8]
Belantamab mafodotin DMBT3AI Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Belantamab mafodotin. Multiple myeloma [2A83] [8]
Elotuzumab DMEYHG9 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Elotuzumab. Multiple myeloma [2A83] [8]
Daratumumab DMKCIUZ Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Daratumumab. Multiple myeloma [2A83] [8]
Romidepsin DMT5GNL Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Romidepsin. Mycosis fungoides [2B01] [8]
Nilotinib DM7HXWT Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Nilotinib. Myeloproliferative neoplasm [2A20] [8]
Ruxolitinib DM7Q98D Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Ruxolitinib. Myeloproliferative neoplasm [2A20] [8]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [8]
Olaparib DM8QB1D Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Olaparib. Ovarian cancer [2C73] [8]
Rucaparib DM9PVX8 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Rucaparib. Ovarian cancer [2C73] [8]
MK-4827 DMLYGH4 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and MK-4827. Ovarian cancer [2C73] [8]
Upadacitinib DM32B5U Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Upadacitinib. Rheumatoid arthritis [FA20] [8]
Baricitinib DM4ONW5 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Baricitinib. Rheumatoid arthritis [FA20] [8]
Tofacitinib DMBS370 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Tofacitinib. Rheumatoid arthritis [FA20] [8]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Valganciclovir and Golimumab. Rheumatoid arthritis [FA20] [10]
Sarilumab DMOGNXY Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Sarilumab. Rheumatoid arthritis [FA20] [8]
Mogamulizumab DMISH0Z Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Mogamulizumab. Sezary syndrome [2B02] [8]
PDX-101 DM6OC53 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and PDX-101. Solid tumour/cancer [2A00-2F9Z] [8]
Trabectedin DMG3Y89 Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [8]
LEE011 DMMX75K Moderate Additive myelosuppressive effects by the combination of Valganciclovir and LEE011. Solid tumour/cancer [2A00-2F9Z] [8]
Pomalidomide DMTGBAX Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Pomalidomide. Systemic sclerosis [4A42] [8]
Plicamycin DM7C8YV Moderate Additive myelosuppressive effects by the combination of Valganciclovir and Plicamycin. Testicular cancer [2C80] [8]
⏷ Show the Full List of 59 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Valganciclovir 450 mg tablet 450 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4716).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
6 Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
7 Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9.
8 Cerner Multum, Inc. "Australian Product Information.".
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.